{
  "timestamp": "2026-01-07T16:06:11.305837",
  "summary": {
    "total_queries": 81,
    "successful_queries": 81,
    "average_precision": 0.0,
    "average_recall": 0.0,
    "average_f1": 0.0
  },
  "detailed_results": {
    "ground_truth": {
      "timestamp": "2026-01-07T15:48:02.339019",
      "total_queries": 81,
      "queries_analyzed": 81,
      "queries_with_errors": 0,
      "ground_truth": [
        {
          "query_id": "DG_001",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_002",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_003",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_004",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_005",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_006",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_007",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_008",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_009",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_010",
          "question": "How does Unknown drug interact with DPYD A348T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_011",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079055T>C in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_012",
          "question": "How does Unknown drug interact with DPYD chr1:g.97305373C>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_013",
          "question": "How does Unknown drug interact with DPYD chr1:g.97450071G>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_014",
          "question": "How does Unknown drug interact with DPYD chr1:g.97720896G>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_015",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573760C>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_016",
          "question": "How does Unknown drug interact with DPYD chr1:g.97193231C>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_017",
          "question": "How does Unknown drug interact with DPYD chr1:g.97193169T>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_018",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306235delA in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_019",
          "question": "How does Unknown drug interact with DPYD chr1:g.97679174G>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_020",
          "question": "How does Unknown drug interact with DPYD chr1:g.97828158C>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_021",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573967C>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_022",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721603A>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_023",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079145G>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_024",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306282G>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_025",
          "question": "How does Unknown drug interact with DPYD chr1:g.97593336A>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_026",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306235delA in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_027",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573918C>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_028",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079073C>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_029",
          "question": "How does Unknown drug interact with DPYD chr1:g.97883365C>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_030",
          "question": "How does Unknown drug interact with DPYD chr1:g.97679126T>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_031",
          "question": "How does Unknown drug interact with DPYD chr1:g.97082458T>C in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_032",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721543A>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_033",
          "question": "How does Unknown drug interact with DPYD chr1:g.97699457G>A in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_034",
          "question": "How does Unknown drug interact with DPYD chr1:g.97515906T>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_035",
          "question": "How does Unknown drug interact with DPYD chr1:g.97234900A>G in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_036",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721569A>C in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_037",
          "question": "How does Unknown drug interact with DPYD chr1:g.97549703G>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_038",
          "question": "How does Unknown drug interact with DPYD chr1:g.97595138G>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_039",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306195C>T in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "DG_040",
          "question": "How does Unknown drug interact with DPYD chr1:g.97515899delG in cancer?",
          "paper_count": 0,
          "top_keywords": [
            "unknown",
            "interact"
          ],
          "keyword_counts": {
            "unknown": 1,
            "interact": 1
          },
          "method": "portal"
        },
        {
          "query_id": "SL_001",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_002",
          "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_003",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_004",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_005",
          "question": "What mechanisms does Olaparib target in breast cancer with p.R346fs?",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_006",
          "question": "What mechanisms does Ceralasertib target in prostate cancer with p.R175H?",
          "search_query": "\"ceralasertib\" AND in prostate cancer",
          "paper_count": 4,
          "top_keywords": [
            "Humans",
            "Indoles",
            "Pyrimidines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Morpholines",
            "Sulfonamides",
            "Animals",
            "Mice",
            "Cell Line, Tumor",
            "Male",
            "Phthalazines",
            "Piperazines",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Xenograft Model Antitumor Assays",
            "DNA Repair",
            "Prostatic Neoplasms, Castration-Resistant",
            "Aged",
            "Middle Aged",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Aged, 80 and over"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_007",
          "question": "What mechanisms does Adavosertib target in ovarian cancer with p.R175H?",
          "search_query": "\"adavosertib\" AND in ovarian cancer",
          "paper_count": 36,
          "top_keywords": [
            "Humans",
            "Female",
            "Pyrazoles",
            "Pyrimidinones",
            "Ovarian Neoplasms",
            "Cell Cycle Proteins",
            "Protein-Tyrosine Kinases",
            "Cell Line, Tumor",
            "Animals",
            "Mice",
            "Protein Kinase Inhibitors",
            "Antineoplastic Agents",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Tumor Suppressor Protein p53",
            "Pyrimidines",
            "Middle Aged",
            "Aged",
            "Gemcitabine",
            "Double-Blind Method",
            "Ovarian cancer"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_008",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_009",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_010",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_011",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_012",
          "question": "What mechanisms does Ceralasertib target in prostate cancer with p.??",
          "search_query": "\"ceralasertib\" AND in prostate cancer",
          "paper_count": 4,
          "top_keywords": [
            "Humans",
            "Indoles",
            "Pyrimidines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Morpholines",
            "Sulfonamides",
            "Animals",
            "Mice",
            "Cell Line, Tumor",
            "Male",
            "Phthalazines",
            "Piperazines",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Xenograft Model Antitumor Assays",
            "DNA Repair",
            "Prostatic Neoplasms, Castration-Resistant",
            "Aged",
            "Middle Aged",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Aged, 80 and over"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_013",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_014",
          "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_015",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_016",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_017",
          "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_018",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.R346fs?",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_019",
          "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.R175H?",
          "search_query": "\"ceralasertib\" AND in ovarian cancer",
          "paper_count": 17,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Indoles",
            "Phthalazines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Morpholines",
            "Pyrimidines",
            "Sulfonamides",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Mice",
            "BRCA1 Protein",
            "BRCA2 Protein",
            "Protein Kinase Inhibitors",
            "Xenograft Model Antitumor Assays",
            "Antineoplastic Agents",
            "DNA Damage"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_020",
          "question": "What mechanisms does Adavosertib target in breast cancer with p.R175H?",
          "search_query": "\"adavosertib\" AND in breast cancer",
          "paper_count": 30,
          "top_keywords": [
            "Humans",
            "Cell Cycle Proteins",
            "Protein-Tyrosine Kinases",
            "Pyrazoles",
            "Pyrimidinones",
            "Female",
            "Cell Line, Tumor",
            "Animals",
            "Mice",
            "Protein Kinase Inhibitors",
            "Breast Neoplasms",
            "Xenograft Model Antitumor Assays",
            "Antineoplastic Agents",
            "Pyrimidines",
            "Drug Resistance, Neoplasm",
            "Nuclear Proteins",
            "Triple Negative Breast Neoplasms",
            "Apoptosis",
            "AZD1775",
            "WEE1"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_021",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_022",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_023",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_024",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_025",
          "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.??",
          "search_query": "\"ceralasertib\" AND in ovarian cancer",
          "paper_count": 17,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Indoles",
            "Phthalazines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Morpholines",
            "Pyrimidines",
            "Sulfonamides",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Mice",
            "BRCA1 Protein",
            "BRCA2 Protein",
            "Protein Kinase Inhibitors",
            "Xenograft Model Antitumor Assays",
            "Antineoplastic Agents",
            "DNA Damage"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_026",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_027",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_028",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_029",
          "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_030",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_031",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.R346fs?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_032",
          "question": "What mechanisms does Ceralasertib target in breast cancer with p.R175H?",
          "search_query": "\"ceralasertib\" AND in breast cancer",
          "paper_count": 14,
          "top_keywords": [
            "Humans",
            "Pyrimidines",
            "Indoles",
            "Morpholines",
            "Sulfonamides",
            "Phthalazines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Female",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Triple Negative Breast Neoplasms",
            "Mice",
            "Antineoplastic Agents",
            "Sulfoxides",
            "Breast Neoplasms",
            "Xenograft Model Antitumor Assays",
            "DNA Damage",
            "Protein Kinase Inhibitors"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_033",
          "question": "What mechanisms does Adavosertib target in prostate cancer with p.R175H?",
          "search_query": "\"adavosertib\" AND in prostate cancer",
          "paper_count": 6,
          "top_keywords": [
            "Humans",
            "Pyrazoles",
            "Cell Cycle Proteins",
            "Protein-Tyrosine Kinases",
            "Pyrimidinones",
            "Male",
            "Animals",
            "Cell Line, Tumor",
            "Mice",
            "Female",
            "Pyrimidines",
            "Antineoplastic Agents",
            "Mice, Nude",
            "Protein Kinase Inhibitors",
            "Prostatic Neoplasms",
            "Drug Synergism",
            "Apoptosis",
            "Xenograft Model Antitumor Assays",
            "Mice, Inbred BALB C",
            "Neoplasms"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_034",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_035",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "search_query": "\"olaparib\" AND in breast cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Antineoplastic Agents",
            "Olaparib",
            "Breast Neoplasms",
            "BRCA1 Protein",
            "Triple Negative Breast Neoplasms",
            "olaparib",
            "Mice",
            "Antineoplastic Combined Chemotherapy Protocols",
            "PARP inhibitor",
            "Poly (ADP-Ribose) Polymerase-1",
            "Apoptosis",
            "breast cancer",
            "Middle Aged"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_036",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_037",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_038",
          "question": "What mechanisms does Ceralasertib target in breast cancer with p.??",
          "search_query": "\"ceralasertib\" AND in breast cancer",
          "paper_count": 14,
          "top_keywords": [
            "Humans",
            "Pyrimidines",
            "Indoles",
            "Morpholines",
            "Sulfonamides",
            "Phthalazines",
            "Ataxia Telangiectasia Mutated Proteins",
            "Female",
            "Piperazines",
            "Cell Line, Tumor",
            "Animals",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Triple Negative Breast Neoplasms",
            "Mice",
            "Antineoplastic Agents",
            "Sulfoxides",
            "Breast Neoplasms",
            "Xenograft Model Antitumor Assays",
            "DNA Damage",
            "Protein Kinase Inhibitors"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_039",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "search_query": "\"olaparib\" AND in prostate cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Male",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Phthalazines",
            "Piperazines",
            "Prostatic Neoplasms",
            "Prostatic Neoplasms, Castration-Resistant",
            "Prostate cancer",
            "Olaparib",
            "Cell Line, Tumor",
            "prostate cancer",
            "Aged",
            "PARP inhibitor",
            "Antineoplastic Combined Chemotherapy Protocols",
            "Animals",
            "Middle Aged",
            "Mutation",
            "Antineoplastic Agents",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "SL_040",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "search_query": "\"olaparib\" AND in ovarian cancer",
          "paper_count": 100,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Poly(ADP-ribose) Polymerase Inhibitors",
            "Piperazines",
            "Phthalazines",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Antineoplastic Combined Chemotherapy Protocols",
            "BRCA1 Protein",
            "Olaparib",
            "Adult",
            "Antineoplastic Agents",
            "Animals",
            "PARP inhibitor",
            "Mice",
            "Drug Resistance, Neoplasm"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        },
        {
          "query_id": "HV_001",
          "question": "How does foods help with [{'compound': 'Vitamin D', 'aliases': ['Cholecalciferol', 'Vitamin D3', 'Calciferol'], 'B_targets': ['VDR', 'TP53 pathway', 'DNA repair', 'Immune function', 'BRCA1'], 'mechanisms': ['Enhances BRCA1 function and homologous recombination repair', 'Modulates TP53 pathway through VDR-dependent transcription', 'Supports T-cell and NK cell function (immune surveillance)', 'Reduces inflammation via NF-\u03baB inhibition', 'May improve platinum sensitivity through DNA repair support'], 'evidence_grade': 'MODERATE', 'evidence_summary': '3 RCTs + large observational studies (n>1200) show survival benefit in ovarian cancer. Serum 25(OH)D >30 ng/mL associated with HR 0.77 for mortality.', 'ovarian_specific_data': {'survival_hr': 0.77, 'sample_size': 1200, 'serum_target': '40-60 ng/mL', 'citation': 'PMID:25489052'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Fat-soluble. Take with meals containing fat for optimal absorption. D3 (cholecalciferol) superior to D2 (ergocalciferol).', 'dosage': '2000-4000 IU daily (target serum 25(OH)D: 40-60 ng/mL). Check levels q3-6 months.', 'safety': 'GOOD', 'safety_notes': 'Monitor serum calcium and 25(OH)D levels. Avoid >10,000 IU daily unless supervised. May interact with digoxin.', 'cost': 'LOW ($10-15/month)', 'food_sources': ['Fatty fish (salmon, mackerel)', 'Egg yolks', 'Fortified dairy', 'Sun exposure (15-30 min daily)'], 'ab_relevance_ovarian': {'tp53_context': 'HIGH - VDR can partially restore TP53-like transcriptional programs', 'hrd_context': 'HIGH - Enhances BRCA1 function and HR repair', 'inflammation_context': 'MODERATE - Reduces NF-\u03baB activity'}}, {'compound': 'Omega-3 Fatty Acids (EPA/DHA)', 'aliases': ['Fish oil', 'EPA', 'DHA', 'Eicosapentaenoic acid', 'Docosahexaenoic acid'], 'B_targets': ['NF-\u03baB', 'COX-2', 'IL-6', 'Membrane integrity', 'Prostaglandins'], 'mechanisms': ['Inhibits NF-\u03baB signaling (anti-inflammatory)', 'Reduces COX-2 expression and prostaglandin E2 (PGE2)', 'Modulates immune cell function and reduces immunosuppression', 'Improves platinum sensitivity by reducing inflammation-driven resistance', 'Stabilizes cell membranes and reduces oxidative damage'], 'evidence_grade': 'MODERATE', 'evidence_summary': '2 RCTs in ovarian cancer show reduced systemic inflammation (CRP -45%) and improved platinum response. Observational data suggests survival benefit with high omega-3 intake.', 'ovarian_specific_data': {'inflammation_reduction': 0.45, 'platinum_sensitization': 0.3, 'cachexia_prevention': 'suggestive', 'citation': 'PMID:28765325, PMID:31234567'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Triglyceride form better absorbed than ethyl ester. Take with meals. Refrigerate to prevent oxidation.', 'dosage': '2-4g EPA+DHA daily (high-dose formulation). Prefer pharmaceutical-grade (low mercury, PCBs).', 'safety': 'GOOD', 'safety_notes': 'May increase bleeding risk with anticoagulants (warfarin, aspirin). Monitor INR. Use pharmaceutical-grade to avoid mercury/contaminants.', 'cost': 'MODERATE ($20-40/month for high-dose pharmaceutical grade)', 'food_sources': ['Fatty fish (salmon, sardines, mackerel)', 'Algae oil (vegetarian DHA)', 'Krill oil'], 'ab_relevance_ovarian': {'inflammation_context': 'HIGH - Directly targets ascites-driven NF-\u03baB/IL-6 axis', 'pi3k_context': 'MODERATE - PI3K/AKT activation drives NF-\u03baB', 'peritoneal_stress_context': 'HIGH - Reduces inflammatory cytokines in ascites'}}, {'compound': 'Folate + Vitamin B12', 'aliases': ['Methylfolate', '5-MTHF', 'L-methylfolate', 'Methylcobalamin', 'B9', 'B12'], 'B_targets': ['DNA synthesis', 'DNA repair', 'Methylation', 'One-carbon metabolism', 'Homocysteine metabolism'], 'mechanisms': ['Provides methyl donors for DNA synthesis and repair (critical for BRCA/HRD)', 'Supports one-carbon metabolism (required for nucleotide synthesis)', 'May reduce chemotherapy-induced DNA damage in normal cells', 'Lowers homocysteine (cardiovascular protection during chemotherapy)', 'Required cofactor for DNA repair enzymes'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Observational data suggests benefit (HR 0.85 for high folate intake). RCT data mixed - some suggest benefit, others neutral. Mechanistic rationale strong for HRD context.', 'ovarian_specific_data': {'observational_hr': 0.85, 'mechanism_plausible': True, 'hrd_context': 'strong rationale', 'citation': 'PMID:26543123'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Use methylfolate (5-MTHF) - active form, bypasses MTHFR polymorphism. Use methylcobalamin (active B12). Avoid folic acid >1000 mcg (synthetic form may mask B12 deficiency).', 'dosage': '400-800 mcg methylfolate + 500-1000 mcg methylcobalamin daily. Higher doses (1-2mg) may be used under supervision.', 'safety': 'GOOD', 'safety_notes': 'High-dose folic acid may mask B12 deficiency (use methylated forms). Avoid mega-doses >5mg folate (conflicting data on cancer risk).', 'cost': 'LOW ($10-15/month)', 'food_sources': ['Leafy greens (spinach, kale)', 'Legumes', 'Eggs', 'Fortified grains', 'Liver'], 'ab_relevance_ovarian': {'hrd_context': 'MODERATE - Supports remaining DNA repair pathways', 'tp53_context': 'LOW - Indirect support for DNA integrity', 'chemo_context': 'MODERATE - May reduce platinum-induced DNA damage'}}, {'compound': 'Curcumin (Turmeric)', 'aliases': ['Turmeric', 'Curcuma longa', 'Diferuloylmethane'], 'B_targets': ['NF-\u03baB', 'COX-2', 'STAT3', 'Apoptosis', 'HSP90'], 'mechanisms': ['Inhibits NF-\u03baB activation (anti-inflammatory)', 'Reduces COX-2 expression', 'May enhance platinum sensitivity via oxidative stress modulation', 'Antioxidant effects (protects normal cells)', 'Inhibits STAT3 (IL-6 signaling)'], 'evidence_grade': 'WEAK', 'evidence_summary': '50+ preclinical studies show synergy with platinum. 2 small RCTs (n=50-80) show mixed results - likely due to poor bioavailability. Liposomal formulations more promising.', 'ovarian_specific_data': {'phase_2_orr': 0.12, 'preclinical_synergy': 'strong', 'bioavailability_barrier': 'critical limitation', 'citation': 'PMID:29030430'}, 'bioavailability': 'POOR', 'bioavailability_notes': 'Only 1-2% absorbed due to poor water solubility and rapid metabolism. MUST use enhanced formulations: liposomal, phytosome (Meriva), or with piperine (black pepper extract, 20mg). Avoid standard curcumin powder.', 'dosage': '500-1000mg curcumin (standardized 95% curcuminoids) + 20mg piperine OR 200-400mg liposomal curcumin daily. Divide into 2-3 doses.', 'safety': 'GOOD', 'safety_notes': 'High doses may cause GI upset. Avoid with blood thinners (warfarin) - may enhance anticoagulation. May interact with chemotherapy (check with oncologist).', 'cost': 'LOW ($15-25/month for basic; $30-50/month for liposomal)', 'food_sources': ['Turmeric powder (add to food with black pepper and fat)', 'Golden milk (turmeric + milk + pepper)'], 'ab_relevance_ovarian': {'inflammation_context': 'MODERATE - Targets NF-\u03baB/COX-2 axis', 'pi3k_context': 'LOW - Modest effect on PI3K/AKT', 'ascites_context': 'MODERATE - May reduce inflammatory cytokines', 'bioavailability_note': 'Clinical benefit requires enhanced formulation'}}, {'compound': 'Green Tea (EGCG)', 'aliases': ['Epigallocatechin gallate', 'EGCG', 'Green tea extract', 'Catechins'], 'B_targets': ['Proteasome', 'Autophagy', 'STAT3', 'VEGF', 'HSP90'], 'mechanisms': ['Inhibits proteasome activity (synergy with platinum-induced protein damage)', 'Induces autophagy (cellular cleanup of damaged proteins)', 'Anti-angiogenic effects (inhibits VEGF)', 'May reduce chemoresistance by targeting cancer stem cells', 'Modulates STAT3 (IL-6 signaling)'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Preclinical data strong (proteasome inhibition + platinum synergy). Human RCT data limited but suggestive. Observational studies show protective association with high green tea intake.', 'ovarian_specific_data': {'preclinical_synergy': 'moderate', 'observational_benefit': 'suggestive (HR ~0.80 for high intake)', 'proteasome_context': 'strong mechanistic rationale', 'citation': 'PMID:27856789'}, 'bioavailability': 'MODERATE', 'bioavailability_notes': 'EGCG has modest bioavailability (~5-20%). Standardized extracts more reliable than tea. Take on empty stomach for better absorption. Avoid with iron supplementation (binds iron).', 'dosage': '400-800mg EGCG daily (standardized extract) OR 3-5 cups green tea daily. Prefer decaffeinated extract if taking high doses.', 'safety': 'GOOD', 'safety_notes': 'High doses (>800mg EGCG) may affect liver enzymes (rare). Monitor liver function if taking other hepatotoxic drugs. Avoid mega-doses >1200mg EGCG.', 'cost': 'LOW ($10-20/month for extract; $5-10/month for tea)', 'food_sources': ['Green tea (3-5 cups daily)', 'Matcha powder (higher EGCG)', 'Green tea extract supplements'], 'ab_relevance_ovarian': {'proteostasis_context': 'MODERATE - Targets proteasome/autophagy (post-platinum stress)', 'inflammation_context': 'LOW-MODERATE - STAT3 inhibition', 'angiogenesis_context': 'MODERATE - VEGF inhibition (complement to bevacizumab)'}}, {'compound': 'NAC (N-Acetylcysteine)', 'aliases': ['N-Acetylcysteine', 'N-Acetyl-L-cysteine', 'NAC', 'Acetylcysteine'], 'B_targets': ['Glutathione', 'Oxidative stress', 'Mitochondria', 'ROS buffering'], 'mechanisms': ['Glutathione precursor (master antioxidant)', 'Reduces platinum-induced oxidative damage (may protect normal cells)', 'Supports mitochondrial function', 'May buffer ROS in peritoneal environment', 'Potential to reduce neuropathy and nephrotoxicity from platinum'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Mechanistic rationale strong. Limited RCT data in ovarian cancer. Some data suggest protection against platinum toxicity (neuropathy, kidney damage) without reducing efficacy.', 'ovarian_specific_data': {'oxidative_stress_reduction': 0.5, 'normal_tissue_protection': 'suggestive', 'platinum_efficacy': 'not compromised in preclinical studies', 'neuropathy_prevention': 'emerging evidence', 'citation': 'PMID:28123456'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Well-absorbed orally. Take on empty stomach for best absorption (or with food if GI upset). Divide into 2-3 doses. IV formulation exists but requires prescription.', 'dosage': '600-1200mg daily (divided doses: 600mg BID or 400mg TID). Higher doses (1800mg) used in some studies.', 'safety': 'GOOD', 'safety_notes': 'May cause nausea/GI upset at high doses (take with food). Generally well-tolerated. Avoid mega-doses >2400mg daily. May interact with nitroglycerin.', 'cost': 'LOW ($15-20/month)', 'food_sources': ['High-protein foods (eggs, chicken, turkey)', 'Whey protein', 'Not typically obtained from diet in therapeutic doses'], 'ab_relevance_ovarian': {'oxidative_stress_context': 'HIGH - Directly buffers peritoneal ROS and platinum-induced damage', 'hrd_context': 'MODERATE - Supports mitochondrial function under repair stress', 'chemo_toxicity_context': 'HIGH - May reduce neuropathy and kidney damage', 'platinum_timing': 'Take 2-3 hours AFTER platinum infusion to avoid antioxidant interference during treatment'}}]?",
          "search_query": "\"foods\" AND in ovarian cancer",
          "paper_count": 99,
          "top_keywords": [
            "Humans",
            "Female",
            "Ovarian Neoplasms",
            "Diet",
            "Middle Aged",
            "Aged",
            "ovarian cancer",
            "Animals",
            "Male",
            "Adult",
            "Prospective Studies",
            "Risk Factors",
            "Mice",
            "Ovarian cancer",
            "Cell Line, Tumor",
            "Neoplasms",
            "Proportional Hazards Models",
            "Breast Neoplasms",
            "Antioxidants",
            "Fast Foods"
          ],
          "keyword_counts": {},
          "method": "portal_analysis"
        }
      ]
    },
    "validation": {
      "timestamp": "2026-01-07T15:54:38.408310",
      "total_queries": 81,
      "successful": 81,
      "failed": 0,
      "total_mechanisms": 0,
      "total_pathways": 0,
      "results": [
        {
          "query_id": "DG_001",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 3.871129,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ee8e3baf-a83f-452e-89bd-38f1e4f28b4d"
        },
        {
          "query_id": "DG_002",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.450004,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d68e74d3-8b0c-4845-a1cf-cc024e3e6904"
        },
        {
          "query_id": "DG_003",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.239025,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "657acfdb-a205-494f-9a9e-fc316ed2c754"
        },
        {
          "query_id": "DG_004",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.238223,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b80da18b-192d-485b-a468-906073f0d4ff"
        },
        {
          "query_id": "DG_005",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.224641,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "7437ee4b-42e6-4a94-a5d7-a5d333c0b644"
        },
        {
          "query_id": "DG_006",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.223804,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "075c1c42-0da8-4bc9-91dd-ea274ad75ef4"
        },
        {
          "query_id": "DG_007",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.220352,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "9567c0c0-c92d-4d0c-9f7b-06bed7b62378"
        },
        {
          "query_id": "DG_008",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.229243,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "119c6bbd-a771-4f99-9349-44bf2c35578f"
        },
        {
          "query_id": "DG_009",
          "question": "How does Unknown drug interact with DPYD in cancer?",
          "elapsed_seconds": 0.23384,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "e357fada-a1b1-48fb-b789-3401f27ad86c"
        },
        {
          "query_id": "DG_010",
          "question": "How does Unknown drug interact with DPYD A348T in cancer?",
          "elapsed_seconds": 0.236964,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "91df72e4-6e18-4052-ac90-5a8c5668dfa5"
        },
        {
          "query_id": "DG_011",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079055T>C in cancer?",
          "elapsed_seconds": 0.223005,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "1dac30be-e348-4605-9e36-38d0e05959d4"
        },
        {
          "query_id": "DG_012",
          "question": "How does Unknown drug interact with DPYD chr1:g.97305373C>T in cancer?",
          "elapsed_seconds": 0.267948,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "dcd4db02-c2c9-48dc-831f-74e5bbec1a20"
        },
        {
          "query_id": "DG_013",
          "question": "How does Unknown drug interact with DPYD chr1:g.97450071G>T in cancer?",
          "elapsed_seconds": 0.269409,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "02446154-adc3-4bca-8faf-95da3f640c72"
        },
        {
          "query_id": "DG_014",
          "question": "How does Unknown drug interact with DPYD chr1:g.97720896G>A in cancer?",
          "elapsed_seconds": 0.25577,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "3284d253-ef2e-4794-a65d-961fb71b7bda"
        },
        {
          "query_id": "DG_015",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573760C>A in cancer?",
          "elapsed_seconds": 0.263475,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "4c255cec-178a-4f9c-9d7b-60a21f19280e"
        },
        {
          "query_id": "DG_016",
          "question": "How does Unknown drug interact with DPYD chr1:g.97193231C>A in cancer?",
          "elapsed_seconds": 0.249312,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "7af80f97-f622-4042-b7f6-73c10a51ac94"
        },
        {
          "query_id": "DG_017",
          "question": "How does Unknown drug interact with DPYD chr1:g.97193169T>A in cancer?",
          "elapsed_seconds": 0.248676,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "27ff43f8-2ed5-4708-98af-5651fb63283c"
        },
        {
          "query_id": "DG_018",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306235delA in cancer?",
          "elapsed_seconds": 0.247125,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "2ece74f1-3d0c-4c25-93de-1406af5a74f2"
        },
        {
          "query_id": "DG_019",
          "question": "How does Unknown drug interact with DPYD chr1:g.97679174G>A in cancer?",
          "elapsed_seconds": 0.242169,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "f74899c8-1b54-4bf0-8bff-a058e148d7f7"
        },
        {
          "query_id": "DG_020",
          "question": "How does Unknown drug interact with DPYD chr1:g.97828158C>A in cancer?",
          "elapsed_seconds": 0.220054,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "7fb16bc6-0930-4577-9cfe-4607fd4b3482"
        },
        {
          "query_id": "DG_021",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573967C>A in cancer?",
          "elapsed_seconds": 0.277772,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "cbecd6ad-2d6e-47a4-9614-9e16f3ad7752"
        },
        {
          "query_id": "DG_022",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721603A>G in cancer?",
          "elapsed_seconds": 0.26814,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "9ce0250c-5935-4306-9fd3-c6ff0fa35790"
        },
        {
          "query_id": "DG_023",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079145G>T in cancer?",
          "elapsed_seconds": 0.257463,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "be0a58a3-9c86-4843-8bce-30bd78f30cdc"
        },
        {
          "query_id": "DG_024",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306282G>A in cancer?",
          "elapsed_seconds": 0.369885,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "68145d0d-6763-461e-acc8-fb84a083c837"
        },
        {
          "query_id": "DG_025",
          "question": "How does Unknown drug interact with DPYD chr1:g.97593336A>G in cancer?",
          "elapsed_seconds": 0.246391,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "e6e5cd4b-8def-4319-ad9e-375683bf64c4"
        },
        {
          "query_id": "DG_026",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306235delA in cancer?",
          "elapsed_seconds": 0.244463,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "2b01f384-53eb-4524-bff2-5573eff3139b"
        },
        {
          "query_id": "DG_027",
          "question": "How does Unknown drug interact with DPYD chr1:g.97573918C>T in cancer?",
          "elapsed_seconds": 0.234624,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "99151abb-90e6-46b8-8866-c89d0d6222e6"
        },
        {
          "query_id": "DG_028",
          "question": "How does Unknown drug interact with DPYD chr1:g.97079073C>T in cancer?",
          "elapsed_seconds": 0.222428,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "e4db50b2-f61d-4739-9eac-92cde6a432a2"
        },
        {
          "query_id": "DG_029",
          "question": "How does Unknown drug interact with DPYD chr1:g.97883365C>T in cancer?",
          "elapsed_seconds": 0.228922,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ea6fb463-9315-42c5-ba1d-1b579271bbef"
        },
        {
          "query_id": "DG_030",
          "question": "How does Unknown drug interact with DPYD chr1:g.97679126T>G in cancer?",
          "elapsed_seconds": 0.246089,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d66f67fb-c489-4faa-9bb6-52fb74786365"
        },
        {
          "query_id": "DG_031",
          "question": "How does Unknown drug interact with DPYD chr1:g.97082458T>C in cancer?",
          "elapsed_seconds": 0.248647,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "3006df25-49e3-437a-9c62-61474c70f01f"
        },
        {
          "query_id": "DG_032",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721543A>G in cancer?",
          "elapsed_seconds": 0.261564,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "54560ba7-0884-4be3-b6fa-85bad164069b"
        },
        {
          "query_id": "DG_033",
          "question": "How does Unknown drug interact with DPYD chr1:g.97699457G>A in cancer?",
          "elapsed_seconds": 0.270678,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "51e2ff8a-7865-4eda-aff6-6b06754cea0e"
        },
        {
          "query_id": "DG_034",
          "question": "How does Unknown drug interact with DPYD chr1:g.97515906T>G in cancer?",
          "elapsed_seconds": 0.227922,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "dcd82868-413b-4d8a-82d2-dd129ba928fa"
        },
        {
          "query_id": "DG_035",
          "question": "How does Unknown drug interact with DPYD chr1:g.97234900A>G in cancer?",
          "elapsed_seconds": 0.396505,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "6032f9f0-5efd-491f-8273-5180c9639500"
        },
        {
          "query_id": "DG_036",
          "question": "How does Unknown drug interact with DPYD chr1:g.97721569A>C in cancer?",
          "elapsed_seconds": 0.247271,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ef1c7fa9-ee21-435f-983e-f31d2f0831d2"
        },
        {
          "query_id": "DG_037",
          "question": "How does Unknown drug interact with DPYD chr1:g.97549703G>T in cancer?",
          "elapsed_seconds": 0.241469,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ab6ab62e-150f-4872-81e6-1b80e4367f45"
        },
        {
          "query_id": "DG_038",
          "question": "How does Unknown drug interact with DPYD chr1:g.97595138G>T in cancer?",
          "elapsed_seconds": 0.246429,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "05a4ebbc-598e-4821-a416-dc4fe1c5bf0c"
        },
        {
          "query_id": "DG_039",
          "question": "How does Unknown drug interact with DPYD chr1:g.97306195C>T in cancer?",
          "elapsed_seconds": 0.249594,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "f9772a2b-ca6f-4c39-9d16-844a4aca7b71"
        },
        {
          "query_id": "DG_040",
          "question": "How does Unknown drug interact with DPYD chr1:g.97515899delG in cancer?",
          "elapsed_seconds": 0.238398,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b23022f4-312b-4a7e-a734-1a687053bcfc"
        },
        {
          "query_id": "SL_001",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "elapsed_seconds": 0.238576,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "67cf5cef-fb6e-4224-bc96-f7af52ae1f76"
        },
        {
          "query_id": "SL_002",
          "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
          "elapsed_seconds": 0.241621,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "48ba3f51-9d51-49b9-9bdf-4bed1ef10de2"
        },
        {
          "query_id": "SL_003",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
          "elapsed_seconds": 0.236197,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "69c376d8-7e2a-4628-8a18-20dab837eb27"
        },
        {
          "query_id": "SL_004",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
          "elapsed_seconds": 0.23697,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "2d66952c-d99c-4754-875e-180e22dcae1d"
        },
        {
          "query_id": "SL_005",
          "question": "What mechanisms does Olaparib target in breast cancer with p.R346fs?",
          "elapsed_seconds": 0.273372,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "a3381c6c-7a88-4d03-976b-386c08d6042f"
        },
        {
          "query_id": "SL_006",
          "question": "What mechanisms does Ceralasertib target in prostate cancer with p.R175H?",
          "elapsed_seconds": 0.247993,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "90de366f-d3cc-4ab5-a09c-a45905e2b609"
        },
        {
          "query_id": "SL_007",
          "question": "What mechanisms does Adavosertib target in ovarian cancer with p.R175H?",
          "elapsed_seconds": 0.260524,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "7ffce802-7b65-44ef-b0fd-33d65f0a3a88"
        },
        {
          "query_id": "SL_008",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "elapsed_seconds": 0.275657,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "dff3f92c-3368-4a77-8a5c-c8feb6b0fa4f"
        },
        {
          "query_id": "SL_009",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "elapsed_seconds": 0.233696,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "5ef86039-4d35-4795-a7bd-ecf644b772ee"
        },
        {
          "query_id": "SL_010",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.234122,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "76da38fc-fe9e-4503-ba54-661ccc4fe7e9"
        },
        {
          "query_id": "SL_011",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "elapsed_seconds": 0.253139,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ad0b0b3c-a783-4217-8db3-a61870c1c562"
        },
        {
          "query_id": "SL_012",
          "question": "What mechanisms does Ceralasertib target in prostate cancer with p.??",
          "elapsed_seconds": 0.242221,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b80e3689-dfd3-42ef-8310-0a680443d2db"
        },
        {
          "query_id": "SL_013",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.247323,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "0891c53e-ed4f-41d3-89e6-d6bfd8f9fc06"
        },
        {
          "query_id": "SL_014",
          "question": "What mechanisms does Olaparib target in breast cancer with p.C61G?",
          "elapsed_seconds": 0.304254,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "be1b0d17-ef9d-4b1b-8f38-8a9e9234d94a"
        },
        {
          "query_id": "SL_015",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
          "elapsed_seconds": 0.24766,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d7b240c5-1016-4298-accd-024a2ce67df9"
        },
        {
          "query_id": "SL_016",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.K3326*?",
          "elapsed_seconds": 0.244477,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "5a020fd8-65c1-4e72-b59b-a98de389bb89"
        },
        {
          "query_id": "SL_017",
          "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
          "elapsed_seconds": 0.230821,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "9942c82c-d410-4261-a202-2bc94a90b0f3"
        },
        {
          "query_id": "SL_018",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.R346fs?",
          "elapsed_seconds": 0.231711,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b47afb00-6ac2-41e9-b3e6-0823d4ca1224"
        },
        {
          "query_id": "SL_019",
          "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.R175H?",
          "elapsed_seconds": 0.231211,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d4b1ea46-bb66-4c05-9e98-118260bcd783"
        },
        {
          "query_id": "SL_020",
          "question": "What mechanisms does Adavosertib target in breast cancer with p.R175H?",
          "elapsed_seconds": 0.227173,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "711096f3-d097-41da-8607-43bdbddac762"
        },
        {
          "query_id": "SL_021",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "elapsed_seconds": 0.224606,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "a2f5005b-ee9f-4715-a0e5-ebfbb09258aa"
        },
        {
          "query_id": "SL_022",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.238517,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "05de1feb-67a0-4491-b10a-e8d0bce7005a"
        },
        {
          "query_id": "SL_023",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "elapsed_seconds": 0.250736,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "32ec9b72-bc04-4f09-95d5-0e776fd4918a"
        },
        {
          "query_id": "SL_024",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "elapsed_seconds": 0.243313,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "05140aca-1adf-45e3-bc12-1cca89c450d0"
        },
        {
          "query_id": "SL_025",
          "question": "What mechanisms does Ceralasertib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.255933,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "a6fe7698-f982-4454-aaab-005cf8200243"
        },
        {
          "query_id": "SL_026",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "elapsed_seconds": 0.233802,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "13461a71-c470-4a16-80bd-0a8bb9701be8"
        },
        {
          "query_id": "SL_027",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.C61G?",
          "elapsed_seconds": 0.240012,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "7abd7cc6-b218-45af-be34-7b665ad79bf2"
        },
        {
          "query_id": "SL_028",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "elapsed_seconds": 0.280679,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b81d1fac-22a2-44b6-9afd-d559fa268ab3"
        },
        {
          "query_id": "SL_029",
          "question": "What mechanisms does Olaparib target in breast cancer with p.K3326*?",
          "elapsed_seconds": 0.365578,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d0a9a50a-6c49-4139-9459-53c763acb15e"
        },
        {
          "query_id": "SL_030",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.K3326*?",
          "elapsed_seconds": 0.265602,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "e470144a-b79c-48e4-a86f-3ce1f4400860"
        },
        {
          "query_id": "SL_031",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.R346fs?",
          "elapsed_seconds": 0.260551,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "1a07850a-0b54-44cc-8cbd-76928f24f4a9"
        },
        {
          "query_id": "SL_032",
          "question": "What mechanisms does Ceralasertib target in breast cancer with p.R175H?",
          "elapsed_seconds": 0.244143,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "131d8d0a-13dd-46e2-ac62-48592baae425"
        },
        {
          "query_id": "SL_033",
          "question": "What mechanisms does Adavosertib target in prostate cancer with p.R175H?",
          "elapsed_seconds": 0.268149,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "039038c2-e1c6-428a-ba37-3e4e4559c2e2"
        },
        {
          "query_id": "SL_034",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.244455,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "d86e9998-0ca2-4025-9501-0704b49f6399"
        },
        {
          "query_id": "SL_035",
          "question": "What mechanisms does Olaparib target in breast cancer with p.??",
          "elapsed_seconds": 0.252229,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "c991f87c-c055-458a-89e4-99c043670801"
        },
        {
          "query_id": "SL_036",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "elapsed_seconds": 0.24469,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "14b97e26-54ab-4a84-b63e-88295fca6d54"
        },
        {
          "query_id": "SL_037",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.??",
          "elapsed_seconds": 0.251824,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "b3b0dc79-044b-4500-b0a3-0c118ecf4b7a"
        },
        {
          "query_id": "SL_038",
          "question": "What mechanisms does Ceralasertib target in breast cancer with p.??",
          "elapsed_seconds": 0.259115,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "3f8b9b3a-46c9-48db-86d0-886d3d304e9b"
        },
        {
          "query_id": "SL_039",
          "question": "What mechanisms does Olaparib target in prostate cancer with p.??",
          "elapsed_seconds": 0.251888,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "ac2e4908-6ae6-4f5c-84c0-00161a99a233"
        },
        {
          "query_id": "SL_040",
          "question": "What mechanisms does Olaparib target in ovarian cancer with p.C61G?",
          "elapsed_seconds": 0.253253,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "395fd578-649d-4ce6-bc9a-5b952eb9e7d4"
        },
        {
          "query_id": "HV_001",
          "question": "How does foods help with [{'compound': 'Vitamin D', 'aliases': ['Cholecalciferol', 'Vitamin D3', 'Calciferol'], 'B_targets': ['VDR', 'TP53 pathway', 'DNA repair', 'Immune function', 'BRCA1'], 'mechanisms': ['Enhances BRCA1 function and homologous recombination repair', 'Modulates TP53 pathway through VDR-dependent transcription', 'Supports T-cell and NK cell function (immune surveillance)', 'Reduces inflammation via NF-\u03baB inhibition', 'May improve platinum sensitivity through DNA repair support'], 'evidence_grade': 'MODERATE', 'evidence_summary': '3 RCTs + large observational studies (n>1200) show survival benefit in ovarian cancer. Serum 25(OH)D >30 ng/mL associated with HR 0.77 for mortality.', 'ovarian_specific_data': {'survival_hr': 0.77, 'sample_size': 1200, 'serum_target': '40-60 ng/mL', 'citation': 'PMID:25489052'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Fat-soluble. Take with meals containing fat for optimal absorption. D3 (cholecalciferol) superior to D2 (ergocalciferol).', 'dosage': '2000-4000 IU daily (target serum 25(OH)D: 40-60 ng/mL). Check levels q3-6 months.', 'safety': 'GOOD', 'safety_notes': 'Monitor serum calcium and 25(OH)D levels. Avoid >10,000 IU daily unless supervised. May interact with digoxin.', 'cost': 'LOW ($10-15/month)', 'food_sources': ['Fatty fish (salmon, mackerel)', 'Egg yolks', 'Fortified dairy', 'Sun exposure (15-30 min daily)'], 'ab_relevance_ovarian': {'tp53_context': 'HIGH - VDR can partially restore TP53-like transcriptional programs', 'hrd_context': 'HIGH - Enhances BRCA1 function and HR repair', 'inflammation_context': 'MODERATE - Reduces NF-\u03baB activity'}}, {'compound': 'Omega-3 Fatty Acids (EPA/DHA)', 'aliases': ['Fish oil', 'EPA', 'DHA', 'Eicosapentaenoic acid', 'Docosahexaenoic acid'], 'B_targets': ['NF-\u03baB', 'COX-2', 'IL-6', 'Membrane integrity', 'Prostaglandins'], 'mechanisms': ['Inhibits NF-\u03baB signaling (anti-inflammatory)', 'Reduces COX-2 expression and prostaglandin E2 (PGE2)', 'Modulates immune cell function and reduces immunosuppression', 'Improves platinum sensitivity by reducing inflammation-driven resistance', 'Stabilizes cell membranes and reduces oxidative damage'], 'evidence_grade': 'MODERATE', 'evidence_summary': '2 RCTs in ovarian cancer show reduced systemic inflammation (CRP -45%) and improved platinum response. Observational data suggests survival benefit with high omega-3 intake.', 'ovarian_specific_data': {'inflammation_reduction': 0.45, 'platinum_sensitization': 0.3, 'cachexia_prevention': 'suggestive', 'citation': 'PMID:28765325, PMID:31234567'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Triglyceride form better absorbed than ethyl ester. Take with meals. Refrigerate to prevent oxidation.', 'dosage': '2-4g EPA+DHA daily (high-dose formulation). Prefer pharmaceutical-grade (low mercury, PCBs).', 'safety': 'GOOD', 'safety_notes': 'May increase bleeding risk with anticoagulants (warfarin, aspirin). Monitor INR. Use pharmaceutical-grade to avoid mercury/contaminants.', 'cost': 'MODERATE ($20-40/month for high-dose pharmaceutical grade)', 'food_sources': ['Fatty fish (salmon, sardines, mackerel)', 'Algae oil (vegetarian DHA)', 'Krill oil'], 'ab_relevance_ovarian': {'inflammation_context': 'HIGH - Directly targets ascites-driven NF-\u03baB/IL-6 axis', 'pi3k_context': 'MODERATE - PI3K/AKT activation drives NF-\u03baB', 'peritoneal_stress_context': 'HIGH - Reduces inflammatory cytokines in ascites'}}, {'compound': 'Folate + Vitamin B12', 'aliases': ['Methylfolate', '5-MTHF', 'L-methylfolate', 'Methylcobalamin', 'B9', 'B12'], 'B_targets': ['DNA synthesis', 'DNA repair', 'Methylation', 'One-carbon metabolism', 'Homocysteine metabolism'], 'mechanisms': ['Provides methyl donors for DNA synthesis and repair (critical for BRCA/HRD)', 'Supports one-carbon metabolism (required for nucleotide synthesis)', 'May reduce chemotherapy-induced DNA damage in normal cells', 'Lowers homocysteine (cardiovascular protection during chemotherapy)', 'Required cofactor for DNA repair enzymes'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Observational data suggests benefit (HR 0.85 for high folate intake). RCT data mixed - some suggest benefit, others neutral. Mechanistic rationale strong for HRD context.', 'ovarian_specific_data': {'observational_hr': 0.85, 'mechanism_plausible': True, 'hrd_context': 'strong rationale', 'citation': 'PMID:26543123'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Use methylfolate (5-MTHF) - active form, bypasses MTHFR polymorphism. Use methylcobalamin (active B12). Avoid folic acid >1000 mcg (synthetic form may mask B12 deficiency).', 'dosage': '400-800 mcg methylfolate + 500-1000 mcg methylcobalamin daily. Higher doses (1-2mg) may be used under supervision.', 'safety': 'GOOD', 'safety_notes': 'High-dose folic acid may mask B12 deficiency (use methylated forms). Avoid mega-doses >5mg folate (conflicting data on cancer risk).', 'cost': 'LOW ($10-15/month)', 'food_sources': ['Leafy greens (spinach, kale)', 'Legumes', 'Eggs', 'Fortified grains', 'Liver'], 'ab_relevance_ovarian': {'hrd_context': 'MODERATE - Supports remaining DNA repair pathways', 'tp53_context': 'LOW - Indirect support for DNA integrity', 'chemo_context': 'MODERATE - May reduce platinum-induced DNA damage'}}, {'compound': 'Curcumin (Turmeric)', 'aliases': ['Turmeric', 'Curcuma longa', 'Diferuloylmethane'], 'B_targets': ['NF-\u03baB', 'COX-2', 'STAT3', 'Apoptosis', 'HSP90'], 'mechanisms': ['Inhibits NF-\u03baB activation (anti-inflammatory)', 'Reduces COX-2 expression', 'May enhance platinum sensitivity via oxidative stress modulation', 'Antioxidant effects (protects normal cells)', 'Inhibits STAT3 (IL-6 signaling)'], 'evidence_grade': 'WEAK', 'evidence_summary': '50+ preclinical studies show synergy with platinum. 2 small RCTs (n=50-80) show mixed results - likely due to poor bioavailability. Liposomal formulations more promising.', 'ovarian_specific_data': {'phase_2_orr': 0.12, 'preclinical_synergy': 'strong', 'bioavailability_barrier': 'critical limitation', 'citation': 'PMID:29030430'}, 'bioavailability': 'POOR', 'bioavailability_notes': 'Only 1-2% absorbed due to poor water solubility and rapid metabolism. MUST use enhanced formulations: liposomal, phytosome (Meriva), or with piperine (black pepper extract, 20mg). Avoid standard curcumin powder.', 'dosage': '500-1000mg curcumin (standardized 95% curcuminoids) + 20mg piperine OR 200-400mg liposomal curcumin daily. Divide into 2-3 doses.', 'safety': 'GOOD', 'safety_notes': 'High doses may cause GI upset. Avoid with blood thinners (warfarin) - may enhance anticoagulation. May interact with chemotherapy (check with oncologist).', 'cost': 'LOW ($15-25/month for basic; $30-50/month for liposomal)', 'food_sources': ['Turmeric powder (add to food with black pepper and fat)', 'Golden milk (turmeric + milk + pepper)'], 'ab_relevance_ovarian': {'inflammation_context': 'MODERATE - Targets NF-\u03baB/COX-2 axis', 'pi3k_context': 'LOW - Modest effect on PI3K/AKT', 'ascites_context': 'MODERATE - May reduce inflammatory cytokines', 'bioavailability_note': 'Clinical benefit requires enhanced formulation'}}, {'compound': 'Green Tea (EGCG)', 'aliases': ['Epigallocatechin gallate', 'EGCG', 'Green tea extract', 'Catechins'], 'B_targets': ['Proteasome', 'Autophagy', 'STAT3', 'VEGF', 'HSP90'], 'mechanisms': ['Inhibits proteasome activity (synergy with platinum-induced protein damage)', 'Induces autophagy (cellular cleanup of damaged proteins)', 'Anti-angiogenic effects (inhibits VEGF)', 'May reduce chemoresistance by targeting cancer stem cells', 'Modulates STAT3 (IL-6 signaling)'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Preclinical data strong (proteasome inhibition + platinum synergy). Human RCT data limited but suggestive. Observational studies show protective association with high green tea intake.', 'ovarian_specific_data': {'preclinical_synergy': 'moderate', 'observational_benefit': 'suggestive (HR ~0.80 for high intake)', 'proteasome_context': 'strong mechanistic rationale', 'citation': 'PMID:27856789'}, 'bioavailability': 'MODERATE', 'bioavailability_notes': 'EGCG has modest bioavailability (~5-20%). Standardized extracts more reliable than tea. Take on empty stomach for better absorption. Avoid with iron supplementation (binds iron).', 'dosage': '400-800mg EGCG daily (standardized extract) OR 3-5 cups green tea daily. Prefer decaffeinated extract if taking high doses.', 'safety': 'GOOD', 'safety_notes': 'High doses (>800mg EGCG) may affect liver enzymes (rare). Monitor liver function if taking other hepatotoxic drugs. Avoid mega-doses >1200mg EGCG.', 'cost': 'LOW ($10-20/month for extract; $5-10/month for tea)', 'food_sources': ['Green tea (3-5 cups daily)', 'Matcha powder (higher EGCG)', 'Green tea extract supplements'], 'ab_relevance_ovarian': {'proteostasis_context': 'MODERATE - Targets proteasome/autophagy (post-platinum stress)', 'inflammation_context': 'LOW-MODERATE - STAT3 inhibition', 'angiogenesis_context': 'MODERATE - VEGF inhibition (complement to bevacizumab)'}}, {'compound': 'NAC (N-Acetylcysteine)', 'aliases': ['N-Acetylcysteine', 'N-Acetyl-L-cysteine', 'NAC', 'Acetylcysteine'], 'B_targets': ['Glutathione', 'Oxidative stress', 'Mitochondria', 'ROS buffering'], 'mechanisms': ['Glutathione precursor (master antioxidant)', 'Reduces platinum-induced oxidative damage (may protect normal cells)', 'Supports mitochondrial function', 'May buffer ROS in peritoneal environment', 'Potential to reduce neuropathy and nephrotoxicity from platinum'], 'evidence_grade': 'WEAK', 'evidence_summary': 'Mechanistic rationale strong. Limited RCT data in ovarian cancer. Some data suggest protection against platinum toxicity (neuropathy, kidney damage) without reducing efficacy.', 'ovarian_specific_data': {'oxidative_stress_reduction': 0.5, 'normal_tissue_protection': 'suggestive', 'platinum_efficacy': 'not compromised in preclinical studies', 'neuropathy_prevention': 'emerging evidence', 'citation': 'PMID:28123456'}, 'bioavailability': 'GOOD', 'bioavailability_notes': 'Well-absorbed orally. Take on empty stomach for best absorption (or with food if GI upset). Divide into 2-3 doses. IV formulation exists but requires prescription.', 'dosage': '600-1200mg daily (divided doses: 600mg BID or 400mg TID). Higher doses (1800mg) used in some studies.', 'safety': 'GOOD', 'safety_notes': 'May cause nausea/GI upset at high doses (take with food). Generally well-tolerated. Avoid mega-doses >2400mg daily. May interact with nitroglycerin.', 'cost': 'LOW ($15-20/month)', 'food_sources': ['High-protein foods (eggs, chicken, turkey)', 'Whey protein', 'Not typically obtained from diet in therapeutic doses'], 'ab_relevance_ovarian': {'oxidative_stress_context': 'HIGH - Directly buffers peritoneal ROS and platinum-induced damage', 'hrd_context': 'MODERATE - Supports mitochondrial function under repair stress', 'chemo_toxicity_context': 'HIGH - May reduce neuropathy and kidney damage', 'platinum_timing': 'Take 2-3 hours AFTER platinum infusion to avoid antioxidant interference during treatment'}}]?",
          "elapsed_seconds": 0.245977,
          "mechanisms": [],
          "pathways": [],
          "evidence_tier": "Insufficient",
          "badges": [],
          "overall_confidence": 0.5,
          "paper_count": 0,
          "has_sub_question_answers": true,
          "has_article_summaries": false,
          "has_moat_analysis": true,
          "run_id": "423440ea-f09a-4321-9309-f95beba5c59e"
        }
      ]
    },
    "metrics": {
      "timestamp": "2026-01-07T16:00:27.702468",
      "total_queries": 81,
      "average_precision": 0.0,
      "average_recall": 0.0,
      "average_f1": 0.0,
      "per_query_metrics": [
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_001",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_002",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_003",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_004",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_005",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_006",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_007",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_008",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_009",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_010",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_011",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_012",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_013",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_014",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_015",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_016",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_017",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_018",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_019",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_020",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_021",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_022",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_023",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_024",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_025",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_026",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_027",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_028",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_029",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_030",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_031",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_032",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_033",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_034",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_035",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_036",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_037",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_038",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_039",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "DG_040",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 2
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_001",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_002",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_003",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_004",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_005",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_006",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_007",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_008",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_009",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_010",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_011",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_012",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_013",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_014",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_015",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_016",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_017",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_018",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_019",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_020",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_021",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_022",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_023",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_024",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_025",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_026",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_027",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_028",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_029",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_030",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_031",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_032",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_033",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_034",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_035",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_036",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_037",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_038",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_039",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "SL_040",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        },
        {
          "precision": 0.0,
          "recall": 0.0,
          "f1": 0.0,
          "query_id": "HV_001",
          "mechanism_count": 0,
          "ground_truth_keyword_count": 20
        }
      ]
    },
    "baselines": {
      "timestamp": "2026-01-07T16:05:58.237255",
      "total_queries": 81,
      "baseline_results": {
        "pubmed_abstract_only": [
          {
            "query_id": "DG_001",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_002",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_003",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_004",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_005",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_006",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_007",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_008",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_009",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_010",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_011",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_012",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_013",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_014",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_015",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_016",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_017",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_018",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_019",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_020",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_021",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_022",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_023",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_024",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_025",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_026",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_027",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_028",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_029",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_030",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_031",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_032",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_033",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_034",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_035",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_036",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_037",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_038",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_039",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "DG_040",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "fluoropyrimidine",
              "testing",
              "variants",
              "clinical",
              "study",
              "chemotherapy",
              "severe",
              "sites",
              "gastrointestinal"
            ],
            "paper_count": 98
          },
          {
            "query_id": "SL_001",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "parpi",
              "clinical",
              "ovarian",
              "olaparib",
              "tumor",
              "maintenance",
              "treatment",
              "therapy"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_002",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "breast",
              "olaparib",
              "cancer",
              "pembrolizumab",
              "efficacy",
              "repair",
              "inhibitors",
              "these",
              "clinical"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_003",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "olaparib",
              "cancer",
              "prostate",
              "clinical",
              "repair",
              "metastatic",
              "treatment",
              "inhibitor",
              "mcrpc"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_004",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "treatment",
              "clinical",
              "olaparib",
              "parpi",
              "primary",
              "therapy",
              "response",
              "maintenance"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_005",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_006",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_007",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "cancer",
              "patients",
              "ovarian",
              "efficacy",
              "adavosertib",
              "clinical",
              "response",
              "phase",
              "treatment",
              "gemcitabine"
            ],
            "paper_count": 9
          },
          {
            "query_id": "SL_008",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "olaparib",
              "breast",
              "inhibitor",
              "approved",
              "treatment",
              "mutations",
              "these",
              "cells"
            ],
            "paper_count": 54
          },
          {
            "query_id": "SL_009",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "prostate",
              "patients",
              "olaparib",
              "cancer",
              "treatment",
              "group",
              "mutations",
              "genes",
              "pathogenic",
              "metastatic"
            ],
            "paper_count": 19
          },
          {
            "query_id": "SL_010",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "ovarian",
              "cancer",
              "patients",
              "variants",
              "olaparib",
              "tumors",
              "missense",
              "identified",
              "genomic",
              "analysis"
            ],
            "paper_count": 11
          },
          {
            "query_id": "SL_011",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "olaparib",
              "cancer",
              "group",
              "patients",
              "control",
              "variants",
              "median",
              "ovarian",
              "homologous",
              "recombination"
            ],
            "paper_count": 5
          },
          {
            "query_id": "SL_012",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_013",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "ovarian",
              "olaparib",
              "cancer",
              "patients",
              "genes",
              "expression",
              "could",
              "combination",
              "sensitivity",
              "inhibitors"
            ],
            "paper_count": 8
          },
          {
            "query_id": "SL_014",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "breast",
              "olaparib",
              "cancer",
              "pembrolizumab",
              "efficacy",
              "repair",
              "inhibitors",
              "these",
              "clinical"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_015",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "treatment",
              "repair",
              "olaparib",
              "parpi",
              "inhibitors",
              "prostate",
              "clinical",
              "survival"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_016",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "treatment",
              "clinical",
              "olaparib",
              "parpi",
              "primary",
              "therapy",
              "response",
              "maintenance"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_017",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "olaparib",
              "breast",
              "treatment",
              "pembrolizumab",
              "ctdna",
              "clinical",
              "testing",
              "response"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_018",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_019",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_020",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "mitotic",
              "clinical",
              "inhibition",
              "kinase",
              "entry",
              "preclinical",
              "cancer",
              "checkpoint",
              "premature",
              "synergizes"
            ],
            "paper_count": 2
          },
          {
            "query_id": "SL_021",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "clinical",
              "olaparib",
              "mutations",
              "tumor",
              "cancer",
              "response",
              "prostate",
              "tumors",
              "survival"
            ],
            "paper_count": 65
          },
          {
            "query_id": "SL_022",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "pathogenic",
              "olaparib",
              "ovarian",
              "homologous",
              "repair",
              "mutations",
              "recombination",
              "tumors"
            ],
            "paper_count": 20
          },
          {
            "query_id": "SL_023",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "olaparib",
              "breast",
              "group",
              "control",
              "variants",
              "missense",
              "ovarian",
              "clinical"
            ],
            "paper_count": 9
          },
          {
            "query_id": "SL_024",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "olaparib",
              "group",
              "control",
              "patients",
              "survival",
              "progression",
              "cohort",
              "median",
              "months",
              "cancer"
            ],
            "paper_count": 1
          },
          {
            "query_id": "SL_025",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "clear",
              "patients",
              "combination",
              "ovarian",
              "against",
              "carcinoma",
              "clinical",
              "treatment",
              "compounds",
              "other"
            ],
            "paper_count": 2
          },
          {
            "query_id": "SL_026",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "olaparib",
              "patients",
              "group",
              "cancer",
              "control",
              "sensitivity",
              "genes",
              "months",
              "homologous",
              "disease"
            ],
            "paper_count": 7
          },
          {
            "query_id": "SL_027",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "treatment",
              "repair",
              "olaparib",
              "parpi",
              "inhibitors",
              "prostate",
              "clinical",
              "survival"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_028",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "parpi",
              "clinical",
              "ovarian",
              "olaparib",
              "tumor",
              "maintenance",
              "treatment",
              "therapy"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_029",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "olaparib",
              "breast",
              "treatment",
              "pembrolizumab",
              "ctdna",
              "clinical",
              "testing",
              "response"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_030",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "olaparib",
              "cancer",
              "prostate",
              "clinical",
              "repair",
              "metastatic",
              "treatment",
              "inhibitor",
              "mcrpc"
            ],
            "paper_count": 100
          },
          {
            "query_id": "SL_031",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_032",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_033",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          },
          {
            "query_id": "SL_034",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "cancer",
              "ovarian",
              "olaparib",
              "cells",
              "which",
              "parpi",
              "resistance",
              "inhibitors",
              "inhibition",
              "treatment"
            ],
            "paper_count": 42
          },
          {
            "query_id": "SL_035",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "olaparib",
              "cancer",
              "ctdna",
              "treatment",
              "mutations",
              "inhibitor",
              "these",
              "genes",
              "pathogenic"
            ],
            "paper_count": 32
          },
          {
            "query_id": "SL_036",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "olaparib",
              "patients",
              "group",
              "control",
              "cancer",
              "homologous",
              "progression",
              "patient",
              "survival",
              "repair"
            ],
            "paper_count": 3
          },
          {
            "query_id": "SL_037",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "cancer",
              "ovarian",
              "variants",
              "genomic",
              "homologous",
              "recombination",
              "tumors",
              "patients",
              "olaparib",
              "identified"
            ],
            "paper_count": 6
          },
          {
            "query_id": "SL_038",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "clear",
              "patients",
              "combination",
              "gynecological",
              "activity",
              "other",
              "relapsed",
              "carcinoma",
              "mutations",
              "subtypes"
            ],
            "paper_count": 1
          },
          {
            "query_id": "SL_039",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "olaparib",
              "survival",
              "repair",
              "months",
              "cohort",
              "control",
              "prostate",
              "treatment",
              "cancer"
            ],
            "paper_count": 12
          },
          {
            "query_id": "SL_040",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [
              "patients",
              "cancer",
              "parpi",
              "clinical",
              "ovarian",
              "olaparib",
              "tumor",
              "maintenance",
              "treatment",
              "therapy"
            ],
            "paper_count": 100
          },
          {
            "query_id": "HV_001",
            "baseline": "pubmed_abstract_only",
            "mechanisms": [],
            "paper_count": 0
          }
        ],
        "chatgpt_direct": [],
        "keyword_matching": [
          {
            "query_id": "DG_001",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_002",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_003",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_004",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_005",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_006",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_007",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_008",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_009",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_010",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_011",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_012",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_013",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_014",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_015",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_016",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_017",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_018",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_019",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_020",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_021",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_022",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_023",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_024",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_025",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_026",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_027",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_028",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_029",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_030",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_031",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_032",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_033",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_034",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_035",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_036",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_037",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_038",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_039",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "DG_040",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_001",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_002",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_003",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_004",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_005",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_006",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_007",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_008",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_009",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_010",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_011",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_012",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_013",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_014",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_015",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_016",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_017",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_018",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_019",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_020",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_021",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_022",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_023",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_024",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_025",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_026",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_027",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_028",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_029",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_030",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_031",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_032",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_033",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_034",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_035",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_036",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_037",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_038",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_039",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "SL_040",
            "baseline": "keyword_matching",
            "mechanisms": []
          },
          {
            "query_id": "HV_001",
            "baseline": "keyword_matching",
            "mechanisms": [
              "apoptosis",
              "angiogenesis",
              "metabolism",
              "resistance",
              "inhibition",
              "activation",
              "pathway",
              "signaling",
              "dna repair",
              "inflammation",
              "oxidative stress",
              "autophagy"
            ]
          }
        ]
      }
    }
  }
}